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VaccinePorcine aminopeptidase N (pAPN) is a cellular receptor of transmissible gastroenteritis virus (TGEV), a
porcine coronavirus. Interaction between the spike (S) protein of TGEV and pAPN initiates cell infection. Small
molecules, especially peptides are an expanding area for therapy or diagnostic assays for viral diseases.
Here, the peptides capable of binding the pAPN were, for the ﬁrst time, identiﬁed by biopanning using a
random 12-mer peptide library to the immobilized protein. Three chemically synthesized peptides
recognizing the pAPN showed effective inhibition ability to TGEV infection in vitro. A putative TxxF motif
was identiﬁed in the S protein of TGEV. Phages bearing the speciﬁc peptides interacted with the pAPN in
ELISA. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays conﬁrmed the protec-
tive effect of the peptides on cell infection by TGEV. Moreover, the excellent immune responses in mice
induced by the identiﬁed phages provided the possibility to develop novel phage-based vaccines.au.edu.cn (X. Ren),
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Transmissible gastroenteritis virus (TGEV) is the causative agent
of transmissible gastroenteritis (TGE), a highly contagious enteric
disease in swine. The typical clinical symptoms of TGE consist of
vomiting, acute diarrhea, and dehydration. Older animals usually
recover, but in newborn piglets mortality rates may reach 100% (Saif
and Wesley, 1992; Laude et al., 1993; Schwegmann-Wessels et al.,
2002; Ren et al., 2008). TGE prevalence causes enormous economic
losses in pig industry. TGEV is an enveloped, single-stranded,
positive-sense RNA virus that belongs to the family Coronaviridae
and order Nidovirales (Enjuanes et al., 2000; Yin et al., 2010). They
own the largest RNA viral genome, about 30 kb. TGEV produces at
least eight subgenomic mRNAs during viral replication and each
mRNA consists of 3′ co-terminal nested sets (Laude et al., 1993;
Vaughn et al., 1995).
Three major structural proteins of coronavirus: the spike (S), the
integral membrane (M) glycoprotein, and the nucleocapsid (N)
protein are translated from mRNAs 2, 5 and 6, respectively (Spaan
et al., 1988; Laude et al., 1993; Almazán et al., 2000). The M protein is
an abundant component of coronaviruses (Rottier, 1995; Ren et al.,
2010b). The M protein as the major interferon inducing component
has been proposed to play a role in innate immune response to
coronaviruses (Charley and Laude, 1988; Laude et al., 1992). Roughlyone-third of TGEV M protein assumes a topology in which part of the
endodomain constitutes a fourth transmembrane segment, thereby
positioning the carboxy terminus of the molecule on the exterior of
the virion (Masters, 2006; Risco et al., 1995). TGEV N phosphoprotein
complexes with the genomic RNA in a beads-on-a-string fashion to
form the nucleocapsid (Suñé et al., 1990; Cavanagh et al., 1994). The S
protein of coronaviruses is a large transmembrane protein with the
amino terminus exposed to the virus surface and the carboxy
terminus inside the virus particle and it assembles into trimers to
form the distinctive viral surface spikes (Delmas and Laude, 1990).
Coronavirus S protein plays an important role in inducing neutralizing
antibodies (Garwes et al., 1978; Jiménez et al., 1986; Laude et al.,
1987; Suñé et al., 1990) and it is also related to host cell tropism
(Jacobs et al., 1986; Schwegmann-Wessels et al., 2003, 2009; Ren
et al., 2006), pathogenicity (Siddell, 1995; Krempl et al., 1997), fusion
(Collins et al., 1982; Spaan et al., 1988), hemagglutination activity
(Krempl et al., 2000; Krempl and Herrler, 2001) and interaction with
its cellular receptors such as porcine aminopeptidase N (pAPN)
(Delmas et al., 1992; Liu et al., 2009; Ren et al., 2010a).
APN, also called CD13 in human is a type II transmembrane
ectopeptidase of 150 kDa that contains a zinc-binding motif (HEIAH)
and forms a noncovalently bound homodimer on the cellular
membrane (Liu et al., 2009). APN was extensively expressed on
various cell lines such as hematopoietic cells of myeloid origin,
ﬁbroblasts, brain cells, and epithelial cells of the liver, kidney, and
intestine, etc. (Tsukamoto et al., 2008; Zhang et al., 2008). It is
reported that aminopeptidase N (pAPN) is a cellular receptor for most
of group 1 coronaviruses including human coronavirus 229E (HCoV-
229E), TGEV, feline coronavirus (FCoV) and canine coronavirus
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Generally, APN as receptors for many coronaviruses are species-
speciﬁc (Delmas et al., 1994; Kolb et al., 1997), although the feline
APN (fAPN) can also serve as a receptor for canine coronavirus, TGEV
and human coronavirus 229E in addition to feline infectious
peritonitis virus (Tresnan et al., 1996). The pAPN consists of several
identiﬁed regions, which include the initiator methionine, cytoplas-
mic topological domain, transmembrane region, cytosolic Ser/Thr-
rich junction region, metalloprotease region, and TGEV spike
glycoprotein-interacting region, respectively (Fig. 1).
Peptide ligands that target a speciﬁc protein surface own broad
applications as therapeutics by interfering protein–protein interac-
tions. Phage display libraries provide a powerful and inexpensive
way to identify such peptides. Phage random peptide library consists
of a pool of billions of peptides that can be produced by the fusion
of random nucleic acid sequences to the N terminus of one of the
capsid protein genes (pVIII or pIII) of a ﬁlamentous bacteriophage
(Cwirla et al., 1990; Devlin et al., 1990; Scott and Smith, 1990). By
optimal biopanning, a single clone of phages with a desired binding
speciﬁcity from a random phage library can be identiﬁed. This
approach has been applied successfully in numerous aspects, in-
cluding antibody engineering (Hayden et al., 1997), peptide and
protein drug discovery and manufacture (Kay et al., 1998), di-
agnostic analysis (Ren et al., 2010c), and vaccine development
(Lesinski and Westerink, 2001).
At present, the precise localization of receptor-binding domains
(RBD) in TGEV S protein remains unclear. At the same time, the RBD-
containing peptides may be useful small molecules for diagnosis and
therapy in viral infection. In this study, we identiﬁed, for the ﬁrst time,
the speciﬁc peptides recognizing pAPN that blocks the binding to
TGEV, based on phage display technology. The peptides competitively
blocked TGEV infection in vitro. They, therefore, can be used as speciﬁc
antiviral inhibitors. A putative TxxF motif was identiﬁed in the S
protein. Moreover, the peptide-containing phages elicited effective
immune response in vivo, demonstrating a potential perspective in
development of phage-based vaccines.Results
Expression of pET-apn
The gene encoding a truncated pAPN with the deletion of
cytoplasmic topological domain and transmembrane region (Fig. 1)
was ampliﬁed using PCR and then cloned into pET30a vector. The
authenticity of the recombinant plasmid pET-apn was conﬁrmed by
DNA sequencing. The pAPN-bearing bacteria were induced with IPTG
to express the protein of interest, after pET-apn was transformed into
host bacteria. SDS-PAGE indicated that the fusion protein was about
112 kDa and the immunoreactivity of this protein was conﬁrmed by
Western blot and immunoﬂuorescence (data not shown).7
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Fig. 1. Schematic drawing of porcine aminopeptidase N. The linear structure of porcine ami
consists of initiator methionine, cytoplasmic topological domain, transmembrane regio
glycoprotein-interacting region, respectively. The number of amino acids in each region is in
bold line shows the chain of pAPN and the broken line shows the length of the cloned pAPN
proportional to the length of the amino acid chain.Enrichment efﬁcacy and binding activity of phages after biopanning
After four rounds of biopanning using the pAPN-protein as an
immobilized target, the enrichment efﬁcacy of phages for each round
was analyzed. The titer of phages in elution buffer and the ampliﬁed
phages was increased with the increased panning times (Table 1). Ten
phage clones were numbered 1 to 10 and picked from the last round
panning and ampliﬁed in host cells. The binding activity of the
selected phages to the target protein was assayed using ELISA. Our
results showed that they had a speciﬁc binding activity to the
pAPN (Fig. 2).Analysis of the peptide sequences
The DNA of the phages was extracted and then the heterologous
genes encoding the peptides on the surface of the recombinant phages
were ampliﬁed by primer-speciﬁc PCR. The DNA sequencing reports
showed that three identical peptides were identiﬁed among the ten
phages (Table 2). Phage numbers 1, 4 and 6 had a consensus peptide
sequence SVVPSKATWGFA named S. Phages 2, 7, 8 and 10 had a
consensus sequence HVTTTFAPPPPR named H. The consensus se-
quence derived from Phages 3, 5 and 9 was FKPSSPPSITLW named F.
The results showed that that the three peptides have sequence
homologies and that a TxxF(AK)PxxP overlapping motif could be
identiﬁed. These identiﬁed motifs were compared with TGEV S
protein sequence. Several TxxF motifs were identiﬁed in the S protein
(Supplementary Fig. 1).Binding activity of peptides to pAPN and its inhibitory effect on cell
infection
ELISA results showed that the three peptides were capable of
binding the pAPN. TGEV coated plates have a higher binding activity
than these peptides. There was no signiﬁcant binding between the IBV
S protein and the anti-pAPN antibody (Fig. 3). Virus infection
inhibition assay showed that ST cells infected by TGEV produced
signiﬁcant cytopathic effect (CPE) at 48 h post infection. In contrast,
the CPE number of peptide-treated ST cells infected by TGEV
decreased in a dose-dependent manner, and the maximum inhibitory
activity of TGEV infection in vitro was achieved at a concentration of
20 μg/ml of each peptides (Fig. 4).
Conventional MTT assays were used to analyze the effect of the
peptides on the proliferation of ST cells infected by TGEV. Our results
showed that OD490 value of peptide-treated ST cells infected by TGEV
was higher than virus infection control, indicating that the prolifer-
ation of cells infected by TGEV was enhanced by the peptides (Fig. 5).
The pre-treatment of the peptides led to increasing number of viable





nopeptidase N (pAPN) was classiﬁed into six regions. The feature key of regions I to VI
n, cytosolic Ser/Thr-rich junction region, metalloprotease region, and TGEV spike
dicated. Region VI (from 717–813 aa) is overlaid within region V (from 65–963 aa). The
used for expression. It should be noted that the sizes of the boxes or the lines are not
Table 1
Titration of the phages post-panning.
Round First Second Third Fourth
Elute 4.6×105 5.54×105 5.92×105 3.6×106
Ampliﬁcation 8.2×1013 1.14×1014 2.38×1014 N/A
The phages at a density of 2×1011pfu/ml were incubated with the pAPN proteins for
each round of panning. The titer of phages in elution buffer (Elute) and in the
ampliﬁcation in the host cells calculated is shown. The phages were selected from the
elute in the fourth round of panning and the phage titer of that time was not measured
(N/A).
Table 2
Deduced amino acid sequences of phage clones.
PCR product number Sequences of deduced amino acids of each peptide
1, 4, 6 S V V P S K A T W G F A (S)
2, 7, 8, 10 H V T TT F A P P P P R (H)
3, 5, 9 F K P S S P P S I T L W (F)
Ten selected phages (phages 1 to 10) were subjected to DNA extraction and PCR. The
deduced amino acid sequences are shown. Three peptide sequences identiﬁed are
shown and designated as S, H and F, respectively (in parenthesis).
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The phages bearing the identiﬁed peptides were used to immunize
mice. At indicated time points, the antibody from the peripheral blood
in the immunized mice was used as primary antibody to detect TGEV
in ELISA. The results showed that the peptides displayed on
ﬁlamentous phages triggered an immune response in mice against
the TGE virions. The pAPN-recognizing peptides elicited stronger
humoral immune response than the control phages bearing complex
peptides, although the control serum might also react with the TGE
virions to certain extent (Fig. 6).
Change of T lymphocyte number from peripheral blood and spleens in
immunized mice
The number of T lymphocytes from peripheral blood and spleens
in immunized mice was quantiﬁed by ﬂow cytometry. The number of
CD4+ T cells increased at 20 days post-immunization in the mice
immunized with the phages compared with the mock-immunized
mice. At 30 days post-immunization, the difference in the CD8+ T cell
number between the immunization group and control became
signiﬁcant (Fig. 7).
Discussion
The APN serves as a cellular receptor for several coronaviruses. In
this study, we aimed at using this protein as target protein for
identifying its ligands and investigating the role of the small
molecules. The prokaryotic system is an optimal choice for achieving
a high-level expression of heterologous protein (Yin et al., 2007). In
our previous studies, we expressed the same protein in Escherichia coliFig. 2. Binding of the selected phages to pAPN in ELISA. Ten selected phages (numbers 1
to 10) and an unrelevant phage (number 11) were incubated with coated pAPN or
bovine serum albumin control (uncoated) in ELISA plates followed by successive
incubation with anti-M13 antibody and HRP-conjugated secondary antibody. OD490
value of individual phage from three parallel wells is shown in y axis; the number of the
phages is shown in x axis.by cloning the gene into a different vector, pGEX 6p-1 (Liu et al.,
2009). The fused protein has a glutathione-S-transferase (GST) tag
with high molecular weight of 26 kDa which might have cross-
reaction with other unrelated proteins. Therefore, we cloned the
truncated pAPN gene into another prokaryotic vector pET-30a that
owns T7 lac promoter and has a small tag (6*Histidine) protein.
Rosetta host strain used in this study is designed to enhance the
expression of eukaryotic proteins that contain rare codons. It supplies
tRNAs for AGG, AGA, AUA, CUA, CCC, and GGA codons on a compatible
chloramphenicol-resistant plasmid named pRARE, which makes the
Rosetta strain a “universal” translation where translation would
otherwise be limited by the codon usage of E. coli (Novy et al., 2001).
Many heterologous proteins have been expressed in this system (Li
et al., 2010a,b; Meng et al., 2010; Ren et al., 2010a,d). In our study, the
high level expression of pAPN was achieved again in this expression
system. The pAPN is a glycoprotein and its biological activity is the
main concern due to the inability of modiﬁcation post-translation in
E. coli. Previously, we generated an anti-pAPN antibody deriving from
a rabbit immunized with pGEX-pAPN. In this study, the bacterially
expressed pET-apn protein was detected in Western blot by using the
anti-pAPN antibody. At the same time, we conﬁrmed that an antibody
against pET-apn protein reacted with transiently expressed pAPN on
the eukaryotic cells in immunoﬂuorescence assays and pre-incuba-
tion of the antibody with cells signiﬁcantly decreased cell infection by
TGEV (data not shown). Taken together, the data indicate that the
pAPN used in this study is biologically active. Interestingly, the
expression of pAPN was achieved only if the transmembrane domain
located at its N-terminus was deleted. The hydrophilicity and antigen
index were analyzed using DNASTAR software, and the results
showed that the ﬁrst 35 amino acids in the N terminus of pAPN are
a strong hydrophilicity region and low antigen index (data not
shown). The results suggest that the transmembrane domain in the
pAPN may affect subsequent translation of pAPN in E. coli.
The application of vaccines is still the major prevention measure
for TGEV infection, although pAPN has been identiﬁed as a cellular
receptor for TGEV (Delmas et al., 1992). The importance of effective
peptides in the drug discovery has been noticed due to their apparent
ability to “home in” on active or biological sites on target proteins (Yi
et al., 2003). It has been found that phage-displayed peptides selected
from combinatorial libraries that interacting with viral proteins or
receptors were capable of blocking infection by hepatitis B virusFig. 3. Binding of the peptides to pAPN. The binding ability of the identiﬁed peptides to
pAPN was investigated in ELISA by coating the pAPN as target protein. The TGE virion
and IBV S protein produced from the same expression systemwere used as positive and
negative controls, respectively. The OD490 value is shown in y axis.
Fig. 4. Inhibitory effect of peptides on TGEV infection. The infectivity of TGEV was
analyzed after ST cells were pre-treated with the identiﬁed peptides. The virus infection
and mock-treated cells were included as controls. The inhibition rate of the peptides at
indicated concentrations is shown in y axis. The 100% infectivity value corresponds to
an average plaque number of 170.
Fig. 6. Phages bearing speciﬁc peptides trigger antibody responses against TGEV. After
the mice were immunized with the peptide-bearing phages, the sera isolated from the
animal at indicated time points were used as primary antibody to detect TGEV coated in
ELISA plates. The mock-immunized mice and the mice immunized with the phages
from the random peptide library were used as controls. The OD490 value is shown.
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Boulanger, 1995), Andes Virus (ANDV) (Hall et al., 2009), Sin Nombre
Virus and Hantaan Virus (Larson et al., 2005). In our study, the
immobilized pAPNwas used as a target for incubationwith the phages
from the 12-mer phage display library. The binding phages were
eluted after four rounds of panning. The increased binding ability
between the phages and the pAPN was indicated by the gradually
increased phage titration following each panning. Three peptide
sequences were obtained from the ten selected phages. The binding of
the peptides to the pAPN protein was somewhat lower than the
binding between the pAPN and TGEV, although it was much higher
than the control, indicating that there are more epitopes on TGEV
necessary for interaction between virion and pAPN. Since the peptides
did not react with IBV S protein expressed in the same system, the
phages do not have cross-reaction with the His-tag protein. Plaque
assays showed that the infectivity of TGEV on the native pAPN-
expressing ST cells was decreased by the pre-treatment of the
individual peptides. There was a slight difference in the abilities of
the peptides to inhibit TGEV infection. Interestingly, the antiviral
ability of each of the three peptides was positively correlated with
their binding ability to pAPN. In our study, MTT assays conﬁrmed the
inhibitory effect of the peptides on TGEV infection. Nonetheless, the
proliferation rate of the infected cells was lower than the mock-
infected cell, although it was improved by pre-treatment of the
peptides. The discrepant results between plaque assays and MTT
assays may be partially attributed to: 1) the latter is often used toFig. 5.MTT assays analyzing the effect of peptides to cell proliferation. The effect of the
peptides on the proliferation of cells infected by TGEV was analyzed by conventional
MTT assays. The OD490 value of the peptides at the maximum non-toxic concentration
(20 μg/ml) is provided.determine the mitochondrial dehydrogenase activities of cells, which
cannot reﬂect the inhibition of cell death or cell respiration totally; 2)
cell apoptosis induced by TGEV may interfere with the MTT results to
a certain extent (Eleouet et al., 1998).
It has been documented that four major antigenic sites of TGEV are
located in the N-terminal half of the S protein (designated S1)
(Delmas et al., 1990). In our study, sequence alignment between the
peptides and TGEV S protein indicated that the three peptides have
the most homology identity in different regions in the S1 protein. We
suppose that the peptide sequences or the counterparts in the S
protein should be important receptor binding domains (RBDs) that
may interact with its cellular receptor of pAPN. The binding of TGEV
S protein to pAPN is required for the initial stage of infection (Delmas
et al., 1992). The interaction between the peptides and pAPN was
investigated using ELISA and virus plaque assays. Interestingly, the
peptides showed an effective binding to pAPN and inhibition to TGEV
infection, although their sequences are not completely identical to the
homologous regions in the S1 protein. The results conﬁrm that short
peptides from combinatorial libraries can act as ‘surrogate’ ligands of
proteins that interact with other proteins if they possess the required
critical residues (Geysen et al., 1985; Ruoslahti and Pierschbacher,
1986; Wells, 1996). The peptides can be used as lead compounds for
further optimization and consequent enhancement of antiviral
activity. In addition to binding to pAPN, TGEV virions treated with
neuraminidase can bind via the S protein to N-acetyl neuraminic acid
or N-glycolyl neuraminic acid moieties on the cell surface (Krempl
et al., 2000; Schultze et al., 1995). It has been proposed that binding
to a surface sialoglycoprotein is required for TGEV as a primary
attachment site to initiate infection of intestinal cells (Schwegmann-
Wessels et al., 2002). Therefore, it would be interesting to screen
the ligands of sialoglycoprotein and analyze their roles in the context
of TGEV infection. There are no structural data and only limited
functional information regarding the spike glycoproteins of corona-
viruses in serogroup 1, which includes HCoV-229E, TGEV, FCoV, and
CCoV, although they all use APN as a receptor to enter cells (Benbacer
et al., 1997; Bonavia et al., 2003; Delmas et al., 1992; Hegyi and Kolb,
1998; Yeager et al., 1992). Therefore, the peptides identiﬁed in this
study or the high homologous regions in the S proteins could bemajor
RBDs of viral S proteins. The peptides are also expected to be viable
alternatives or peptide-based drugs to antibodies in prevention of
TGEV infection. In addition, the binding domain of the S protein on its
receptor has been mapped starting at amino acid 506 and shown to
correspond to the domain recognized by neutralizing antibodies
(Godet et al., 1994). In our study, we identiﬁed a TxxF by phage
display and four TxxF motifs were found in the domain. Interestingly,
three such motifs also existed in the other part of the S protein.
Further work will be done to analyze the biological role of the
identiﬁed motif in the S protein.
Fig. 7. Changes of T lymphocytes from peripheral blood and spleens of the immunized mice. The T lymphocytes from the peripheral blood and spleens in immunized mice were
isolated. The number of T cell subsets was quantiﬁed by ﬂow cytometry. The number of CD4+ and CD8+ T cells in the peripheral blood is shown in A and B, respectively. The number
of CD4+ and CD8+ T cells in the spleens is shown in C and D, respectively.
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(PRCV), a respiratory mutant of TGEV, has decreased the risk of TGE
to some extent, because neutralizing antibodies elicited by the
avirulent PRCV can provide cross-protection against TGEV infection
(Schwegmann-Wessels and Herrler, 2006). Nevertheless, TGE prev-
alence is often reported and some TGEVs are being isolated in
different regions in China, indicating that TGEV infection is still
threatening to the Chinese pig industry (Ao et al., 2006; Bai, 2005).
Currently, vaccination is the major prophylaxis measure against TGEV
infection. Many studies have provided direct or indirect evidence for
the involvement of S protein in inducing a protective immune
response or in viral pathogenicity (Daniel and Talbot, 1990; Torres
et al., 1996; Krempl et al., 1997; Wang et al., 1992).
TGEV S protein derives from a 1447-amino acid-long precursor
polypeptide of which a 16-residue signal peptide is removed
(Rasschaert and Laude, 1987). S is the only protein that induces
antibodies that neutralize in the absence of complement (Godet et al.,
1991; Jiménez et al., 1986; Pulford and Britton, 1991; Suñé et al.,
1990). Investigations of its antigenic structure have led to the
identiﬁcation of four to ﬁve major groups of B-cell dependent
epitopes, all located in the S1 part of the polypeptide chain (Correa
et al., 1990; Delmas et al., 1986, 1990; Gebauer et al., 1991; Enjuanes
et al., 1992; Godet et al., 1994). Another signiﬁcant achievement of
this work is the demonstration that the identiﬁed phages bearing the
speciﬁc peptides in their N-terminal region of major coat protein PVIII
may induce speciﬁc humoral immune responses and an enhanced
cell-medicated immunity. The serum antibody of the immunizedmice
can react with TGE virions, indicating that the phage displaying
speciﬁc peptides can mimic the natural epitopes of the S protein. In
this study, we included themixed phages from a 12-mer phage library
as control for immunizing the mice. In our binding assays, a relative
high background was observed between TGEV and the unrelevant
phages. On one hand, we speculate that there are TGEV ligands in the
library that we did not identify. On the other hand, the heterologous
genes were expressed in the PVIII of the phages. It might be possible
that other components of the phages may have binding activity to
TGEV. More work is needed to conﬁrm our hypotheses.The number of CD4+ and CD8+ T lymphocytes in the spleens and
peripheral blood of the immunized mice increased at 10 days post-
immunization. Our ﬁndings are interesting, and it seems that the
phages bearing heterologous peptides may stimulate T lymphocyte-
mediated immune response and phage-based vaccines can be used as
excellent heterologous antigens recognized by speciﬁc antigen-
presenting cells, initiating host immune responses. Since the global
abundance of phages and our increasing ability to exploit them,
further elucidation of mechanisms of phage-mediated immunization
may facilitate the rational design of novel phage-based vaccines. In
addition, compared with peptide-based vaccines, the phage-based
vaccine owns advantages in production cost and efﬁciency.
In conclusion, we have obtained the peptide sequences that
recognize the pAPN protein using phage display library. The
chemically synthesized peptides block cell infection by TGEV through
competition binding the viral cellular receptor. The putative RBDs are
localized by sequence alignment between the peptides and TGEV S
protein. Since many coronaviruses in group I use APN as receptor, the
peptides selected in this study may be candidates for their molecule
inhibitors. The phages bearing the speciﬁc peptides may elicit both
humoral and cellular immune responses, indicating that the present
methodology has the potential to develop novel phage-based novel
vaccines.
Materials and methods
Expression of recombinant plasmid bearing pAPN
Recombinant plasmid, pcDNA3.1-apn containing full-length pAPN
(a gift from Dr. Georg Herrler of Institute for Virology, University of
Veterinary Medicine Hannover, Germany) was used as template for
PCR amplifying a truncated pAPN gene starting from amino acid 36
using sense primer P1–5′ GGGGGGATCCGAGAAGAACAAGAATGCC 3′,
and antisense primer P2–5′ CCCCCTCGAGTGCTGTGCTCTATGAACCA
3′. Underscored parts contain BamHI and XhoI restriction sites,
respectively. The PCR proﬁle included 95 °C for 5 min, 30 cycles of
95 °C for 1 min, 57 °C for 30 s, 72 °C for 3 min, and then a ﬁnal
304 X. Ren et al. / Virology 410 (2011) 299–306extension of 72 °C for 10 min. The puriﬁed PCR product was inserted
in the same sites of pET-30a vector by conventional cloning
techniques, resulting in a recombinant plasmid designated pET-apn.
After pET-apn was transformed into E. coli strain BL21(DE3) pLysS
(Novagen, Germany), expression of the gene of interest was induced
by isopropyl β-D-thiogalactoside (IPTG) at a ﬁnal concentration of
1 mM at 37 °C. The bacterially expressed protein was identiﬁed in
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), puriﬁed by gel-puriﬁcation method and used to generate a
rabbit anti-pAPN antibody as previously described (Liu et al., 2009).Virus binding blocking assay
Transmissible gastroenteritis virus (TGEV, Purdue 46-MAD strain,
a gift from Dr. Luis Enjuanes, Centro Nacional de Biotecnología,
CSIC, Madrid, Spain) was used for virus infection assays. To analyze
the blockade of the anti-pAPN antibody to TGEV infection, ST cells in
6-well plates were incubated with the antibody achieved in this study
at 37 °C for 1 h. After complete washing, TGEV at an MOI (multiplicity
of infection) of 10 was used to infect the cells for 1 h. The cells were
washed three times with PBS and the inoculums were replaced with
1% (w/v) methylcellulose in EMEM (1 ml/well) followed by incuba-
tion for 48–72 h. Unrelated control rabbit sera were included as
control. The wells were subjected to virus-plaque reduction assay
using crystal violet staining (Li et al., 2009; Ren et al., 2008).Biopanning and enrichment analysis
The puriﬁed pAPN was used as the target protein and subjected to
biopanning using a Ph.D.-12 Phage Display Peptide Library Kit. The
procedure was performed according to the manufacturer's instruc-
tions with modiﬁcation (New England Biolabs, USA). Brieﬂy, the
protein of interest at a concentration of 10 μg/well in 0.1 M NaHCO3
(pH 8.6) buffer was coated onto 96-well plates overnight at 4 °C. Then
the plates were blocked for 1 h at 4 °C with PBS containing 1% BSA
followed by six times washing with TBST (50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 0.1% [vol/vol] Tween 20). The phage library diluted in
TBST was added into the plate at a ﬁnal concentration of 2×1011pfu/
ml (100 μl/well) at room temperature for 30 min with gentle rocking.
Unbound phage was removed by 10 times washing with TBST. Bound
phage was eluted using 100 μl elution buffer (0.2 M glycine–HCl, pH
2.2). The eluates neutralized with 15 μl 1 M Tris–HCl (pH 9.1) were
ampliﬁed in E. coli ER2738 bacteria. The phages were puriﬁed by
polyethylene glycol precipitation according to the manufacturer's
instructions. Four rounds of panning were performed and the phage
concentrations in the elution buffer and after ampliﬁcation in host
cells were tittered.Binding activity analyzed by ELISA
The pAPN protein was coated onto ELISA plates as above (10 μg/
well). In parallel, BSA was used as control. The following day,
the plates were blocked for 1 h at room temperature with TBSB
(50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% BSA) at room
temperature for 2 h. The plates were incubated with the selected
phages and an unrelevant control phage at a concentration of
1.5×1011pfu/well for 1 h at 37 °C after TBST washing. Subsequently,
M13 polyclonal antibody (Abcam, 1:1000 diluted in TBSB) was
added into the wells for another 1 h at 37 °C, after washing six times
with TBST. The wells were incubated with HRP-conjugated anti-
rabbit IgG antibody (Sigma, dilution 1:1000). The color was
developed using o-phenylenediamine (OPD) and the optical density
(OD) value was read using an ELISA reader at a wavelength of
490 nm. Each experiment was performed in triplicate.Sequencing and peptide synthesis
Ten positive phage clones were ampliﬁed and precipitated with
polyethylene glycol/NaCl. DNA of individual phagewas puriﬁedwith a
plasmid extraction kit (Nanjing Keygen Biotech. Co., Ltd, China). The
genes encoding the exogenous peptides of M13 were ampliﬁed with
the DNA templates using primers: sense primer 5′-TCACCTCGAAAG-
CAAGCTGA-3′ and anti-sense primer 5′-CCCTCATAGTTAGCG TAACG-
3′. The PCR products were sequenced and the deduced amino acid
sequences were compared with transmissible gastroenteritis virus
TGEV S protein (GenBank accession number M94101). Peptides
derived from the biopanning were synthesized in the Tianma Peptide
Engineering Company, Suzhou, China.
Speciﬁcity and antiviral activity of selected peptides
The individual peptide was diluted in NaHCO3 (pH 8.6) buffer at a
ﬁnal concentration of 100 μg/ml. Puriﬁed TGEV and infectious
bronchitis virus (IBV) S protein at the same concentration were
used as controls. All the proteins were coated in ELISA plates at 37 °C
overnight. Puriﬁed pAPN protein (60 μg/ml) was added into the wells
(100 μl/well) at 37 °C for 1 h. After rinsing, the wells were incubated
with anti-pAPN antibody (dilution 1:1000) for another 1 h. The wells
were incubated with HRP-conjugated goat anti-rabbit IgG antibody at
room temperature for 1 h, after a complete washing. The ELISA results
were recorded at a wavelength of 490 nm as above.
The non-toxic concentration of the peptides to cells was
determined using trypan blue staining andMTT [3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide] assays (Sui et al., 2010).
ST cells in 6-well plates were incubated with serially diluted peptides
at 37 °C for 1 h. The cells were washed three times with PBS and
infectedwith TGEV at anMOI of 10 at 37 °C for 1 h. The cells were then
overlaid with 1% (w/v in serum-free DMEM) methyl-cellulose and
subjected to plaque analysis as above. Mock treated and virus infected
cells were used as controls.
MTT assay
ST cells in 96-well plates were incubated with serially diluted
peptides at 37 °C for 1 h. TGEV at an MOI of 10 was used to infect the
cells at 37 °C for 48–72 h. Subsequently, the wells were washed three
times with PBS and MTT (5 mg/ml) was added (10 μl/each well) at
37 °C for 4 h. The supernatant was discarded and dimethyl sulfoxide
was added (100 μl/well) into each well for 10 min with gentle
shaking. The OD490 of the wells was determined using a plate reader.
In parallel, mock-infected and virus-infected cells were included as
control.
Animal vaccination and immune response analysis
Healthy Kunming mice (6–7 weeks age) were purchased from
Harbin Veterinary Research Institute, China. The mice were divided
into ﬁve groups (15 mice/group). They were mock-immunized group
(M), phages expressing F peptide group (F), phages expressing S
peptide group (S), phages expressing H peptide group (H) and a mixed
phage from the phage library used as control. For the ﬁrst vaccination,
200 μl peptide-expressing phages (at a titer of 1.5×1011pfu/ml) were
mixed with equal volume of Freund's complete adjuvant and the
immunogen was injected to the mice (200 μl/mouse) intramuscularly.
Ten days later, the mice received the same antigen mixed with equal
volume of Freund's incomplete adjuvant. Ten days later, the mice were
injected with the phages alone. Each 10 days post-immunization, the
lymphocytes of peripheral blood collected from the eye artery and the
spleens of the immunized mice (5 mice/group) were isolated with
lymphocyte separation solution (Invitrogen, USA) according to the
manufacturer's instruction. The cells were suspended in PBS at a
305X. Ren et al. / Virology 410 (2011) 299–306density of 1×107cells/ml. The cells (500 μl/each sample) were
centrifuged at 3000 g for 5 min and then washed two times with
cold PBS. They were incubated with FITC-conjugated anti-CD4+ T cell
antibody (Zhongshan, China) and PE-conjugated anti-CD8+ T cell
antibody (Zhongshan, China) at 4 °C for 30 min. The antibodies were
1:1000 diluted in PBS. The cells were washed, re-suspended with PBS
and subjected to ﬂow cytometry analysis. At the same time, TGE virions
(10 μg/well) were coated in ELISA plates and the serum isolated from
the immunized mice was used as primary antibody followed by
incubation with HRP-conjugated second antibody at each 10 days post-
immunization. The OD490 value was read using an ELISA plate reader.
Statistical analysis
The data were analyzed using Student's t-test, and were expressed
as mean value±standard error of the mean (S.E.M.). The P
valueb0.05 was considered statistically signiﬁcant.
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